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1. Introduction
Short chains fatty (SCFAs) acids are organic fatty acids that are the major products of bacterial
fermentation of undigested dietary fiber and resistant starch in the colon. Propionate, acetate
and butyrate are the main SCFAs produced from fermentation and serve as fuel for colono‐
cytes. SCFAs serve as regulators of intracellular pH, cell volume, and other functions associ‐
ated with ion transport. Moreover, SCFAs act as regulators of proliferation, differentiation and
gene expression. Our recent studies reported that SCFAs promote autophagy in colon cancer
cells. In this chapter, the regulation of autophagy by short chain fatty acids in colon cancer
cells will be discussed in details including the mechanism of action.
2. Short chain fatty acids and the colon
Short chain fatty acids are organic fatty acids with 1 to 6 carbon atoms and the major products
of bacterial fermentation in the human large intestine. Those are mostly derived from poly‐
saccharides, oligosaccharides, proteins, peptides and glycoproteins precursors by anaerobic
microorganisms [1]. Diets high in fiber, resistant starches and complex carbohydrates lead to
an increase in the levels of SCFAs. The principal SCFA involved in mammalian physiology
are acetate c2, propionate c3 and butyrate c4. Formate, valerate, caproate, lactate and succinate
are other fermentation products which are produced but to a lesser extent [2]. The scope of
this chapter will be limited to propionate, butyrate and acetate.
In the colon, short chain fatty acids are absorbed at the same time as sodium and water
absorption. Two mechanisms of absorption have been proposed. During diffusion of protonat‐
ed SCFAs, luminal protons (Na+/H+ exchange, K+ H+-ATPase or bacterial metabolic activity)
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acidify the colonic lumen. This creates a pH between the colonic lumen compared to the
systemic circulation. This pH gradient can promote the diffusive movement of SCFAs. With
anion exchange, a family of anion exchangers mediates SCFAs and HCO3 exchange and entry
across the membrane[3]. Once absorbed, SCFAs are used preferentially as fuel for colonic
epithelial cells [4]. Butyrate is used preferentially over propionate and acetate. Those SCFAs
are later transported to the liver. There, propionate acts as a substrate for gluconeogenesis and
inhibits cholesterol synthesis in hepatic tissue. Acetate is utilized in the synthesis of long chain
fatty acids, glutamine, glutamate and beta-hydroxybutyrate [2, 4]. Over the last a few decades,
understanding the role of short chain fatty acids in the gastrointestinal physiology has grown
considerably. They are attractive because of their role as potential therapeutic agents in
diversion colitis, ulcerative colitis, radiation proctitis, pouchitis and antibiotic- associated
diarrhea [4]. Furthermore, SCFAs have anti-tumor activities in colon cancer by promoting
autophagy and apoptosis. In the next section, the role of SCFAs in cancer, mostly in the colon
will be discussed.
Figure 1. Nomenclature of short chain fatty acids (SCFAs). Different SCFAs (acetate, propionate and butyrate) are illus‐
trated in this figure.
3. The role of short chain fatty acids in colon cancer
Diet has a considerable influence on the risk of colon cancer. A diet high in fat has been
considered to promote colon cancer while increased fiber and complex carbohydrates in the
diet may protect against colon cancer. Butyrate is believed to be mostly responsible for the
tumor inhibitory effects of dietary fiber. Sodium butyrate is known to be an effective inducer
of cell differentiation. Colorectal cancer cells treated with sodium butyrate showed a more
differentiated cell state [5, 6]. It is believed that the protective effect of dietary fibers is
associated with butyrate production in the colon which possibly decreases the occurrence of
neoplasia in colonocytes. For example, in reference [7], fibers associated with high butyrate
were protective against colon cancer. Patients with familial polyposis (FAP) syndrome develop
hundreds to thousands of begin tumors of the colon, some of which will progress to colon
cancer if not removed. These FAP patients produced less butyrate than healthy controls and
patients without polyps. All the studies suggest that butyrate has a protective effect against
colon cancer. In the next section, different mechanisms of action of short chain fatty acids on
colon cancer will be discussed.
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4. Mechanisms of action of short chain fatty acids on colon cancer cells
Different mechanisms of action has been proposed through which sodium butyrate regulate
different genes to exert an inhibitory effect on colon cancer development. Sodium butyrate
induces growth inhibition in colon cancer cells by promoting histone hyperacetylation and
induction of the cell cycle inhibitor p21 [8]. Other short chain fatty acids such as propionate
and valerate were also shown to inhibit cell tumor cells but to a lesser extent than butyrate.
However for acetate, no effects were observed on cell proliferation when it was used at a
concentration of 20 mM [9]. Cells other than colonocytes, mainly smooth muscle cells are also
present in the colon. The effect of SCFAs on colon smooth muscle cells was quiet different.
Sodium butyrate promotes the proliferation of smooth muscle cells. Propionate also promotes
colon smooth muscle cells proliferation to a lesser extent than butyrate while acetate had no
effects [9]. The cell growth inhibitory effect of butyrate on colon cancer cells is attributed to its
ability to induce histone hyperacetylation through inhibition of histone deacetylase (HDAC).
Histone hyperacetylation usually results in relaxation of chromatin, thus making DNA more
accessible to transcription factors. For example in reference [10], the cell cycle inhibitor p21
gene was increased and involved in the butyrate effect on colon cancer cell proliferation. The
promoter region of p21 was shown to harbor butyrate-responsive elements. Upon butyrate
treatment, p21 was induced due to HDAC inhibition resulting in G1 phase arrest [9, 11-13].
Figure 2. Mechanism of inhibition of colon cancer cells by short chain fatty acids. Short chain fatty acids, particularly
butyrate can inhibit colon cancer by different mechanisms. In this figure, treatment of colon cancer cells with butyrate
leads to the activation of the cycle inhibitor p21, followed by cell cycle arrest at G1 phase and induction of apoptosis.
Moreover, SCFAs treatment can promote the inhibition of histone deacetylase, leading to histone hyperacetylation
and availability of chromatin structure for binding by different transcription factors. Both histone hyperacetylation
and cell cycle protein p21 inhibit colon cancer growth.
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Sodium butyrate also inhibits colon cancer cell invasion by activating tissue inhibitor matrix
metalloproteinase (TIM) 1- and 2, thus inhibiting the activity of metalloproteinases (MMPs).
Furthermore, sodium butyrate reduces the adherence of colon cancer cells to the basement
membrane protein laminin substrate via fibronection or type IV collagen resulting in the
inhibition of cancer growth. Inflammatory cytokines such as IL-4 and TNF-α also play a role
in the inhibitory role of butyrate in colon cancer [14]. G-protein coupled receptors are also
found to play a role on colon cancer and their role will be discussed in the next section.
Figure 3. Other mechanisms used by short chain fatty acids to inhibit colon cancer carcinogenesis. Treatment with
SCFAs can inhibit the destruction of the basement membrane through the stimulation of the inhibitor of metallopro‐
teinases (TIM). TIM will inhibit metalloproteinases and prevent them from destroying the basement membrane. SCFAs
also inhibit the adherence of colon cancer cells to the basement membrane by reducing fibronection of type IV colla‐
gen levels.
5. The roles of short chain fatty acid receptors GPR41 and GPR43 on colonic
functions
G-protein coupled receptors (GPCRs) consist of a large and diverse family of proteins that
mainly transduce extracellular stimuli to intracellular signals. GPRC family is among the
largest and more diverse family of proteins in the mammalian genome and contain 7 spanning
membrane helixes, an extracellular N-terminus and an intracellular C-terminus. GPCRs can
be coupled by at least 18 Gα which forms a heterodimer with Gβ subunits, which have at least
5 types, and Gγ subunit, of which there are at least 11 types. Over 800 GPCRs have been
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identified in the human genome. The family of GPCR protein is activated upon binding of a
ligand or agonist on the extracellular N-terminus that leads to a conformational change and
activation of the G-protein heterodimer. At least 50 GPCRs have unknown ligands and are
referred as orphans. Depending on the type of GPCRs that is being activated, diverse down‐
stream signaling will be activated.GPRCs respond to different stimuli such as light, neuro‐
transmitters, amino acids, hormones and activate different signaling pathways [15, 16].
Recently, short chain fatty acids (acetate, propionate and butyrate) were reported as ligands
for two orphan GPRCs, GPR41 and GPR43. GPR43 is expressed in immune cells whereas
GPR41 is present in blood vessel endothelial cells, particularly in adipose tissue with significant
expression also in immune cells and endothelial cells of other tissues [17]. Both GPR41 and
GPR43 are expressed in colonic mucosa suggesting their role in the normal development or
functions of the colon tissue [16]. A study by Tang and al. revealed more information on the
function of GPR43 in colon cancer. Immunohistochemistry showed a reduction of GPR43 in
human colon cancers compared to normal human colon tissues. No epigenetic changes such
as promoter hypermethylation or chromatin compaction due to histone deacetylation (HDAC)
were found responsible for the repression or silencing of GPR43 in colon cancer. In order to
determine the function of GPR43 in colon cancer, GPR43 was restored in colon cancer cells.
Treatment of those GPR43 expressing cells with short chain fatty acids propionate and butyrate
rendered the cells more sensitive, caused cell death and promoted cell cycle arrest at Go/G1
phase. The study suggested that loss of GPR43 expression may contribute to colon cancer
development and progression [18]. In the next section, the role of short chain fatty acids in the
fate of colon cancer cells will be discussed.
 
Figure 4. Mechanism of GPR43 role as a tumor suppressor in colon cancer. Treatment of colon cancer cells with SCFAs
(propionate) results in binding of the GPR43 on the extracellular surface. This leads to the activation of intracellular
downstream signaling such as increase in cell cycle protein p21 and CDK1/2 while cyclin D3 is increased resulting in
cell cycle arrest at Go/G1 phase. Propionate treatment also stimulates different caspases which activates apoptosis
and death of colon cancer cells.
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6. Regulation of autophagy by short chain fatty acids
Short chain fatty acids were initially reported to induce apoptosis (type I programmed cell
death)  in  colon  cancer.  Treatment  of  colon  cancer  cells  with  butyrate  inhibited  cell
proliferation, promoted apoptosis in 79% of cells through the activation of caspase-3 and
the degradation of PARP [19] [20].  Recently,  SCFAs, particularly propionate was report‐
ed  to  induce  autophagy  as  evidenced  by  an  increased  LC3  punctuates  formation  and
upregulation of LAMP-2 [21]. In this section, the regulation of autophagy by short chain
fatty  acids  will  be  discussed.  The  mechanisms  involved  will  be  discussed  in  details,
including the signaling pathways involved.
6.1. Mechanism of autophagy regulation by short chain fatty acids in colon cancer
In autophagy studies, it is very well established that the mammalian target of rapamycin
(mTOR) negatively regulates autophagy. The autophosphorylation at Ser2481 is regarded
as  an  indicator  of  its  catalytic  activity.  Post  propionate  treatment  of  colon  cancer  cells
HCT116, a strong time dependent reduction in the phosphorylation state at Ser2481 was
observed,  while  there  were  no changes  in  the  total  mTORC levels.  Another  key down‐
stream effector of mTOR, p70S6K, whose phosphorylation status at Thr389 reflects mTOR
activity, whereas phosphorylation at Thr421/Ser424 is thought to activate p70S6K was also
performed.  Following  propionate  treatment,  a  reduced  phosphorylation  of  p70S6K  at
Thr389  was  observed  by  7  h  confirming  that  downregulation  of  the  mTOR  signaling
pathway is  a  mechanism for propionate to induce autophagy.  The group then hypothe‐
sized that propionate must induce mTOR signaling from the inhibition of PI3/Akt pathway,
which was shown to activate mTOR in response to the introduction of nutrient and growth
factors. However, no changes in the phosphorylation state of Akt at S473 or Thr308 or the
total  Akt  were  observed  post  propionate  treatment.  Another  pathway  which  acts  up‐
stream of the mTOR pathway, the AMP-activated protein kinase (AMPK) [22], an inhibi‐
tor of the mTOR protein and a sensor of cellular bioenergetics, was significantly activated.
Interestingly,  propionate mediated AMPK activation caused a decrease in ATP levels  in
colon cancer cells due to a breach of the mitochondrial membrane potential. In more details,
propionate depolarized the mitochondrial membrane, which was shown using mitotrack‐
er deep red, a dye that stains the mitochondria in live cells and accumulates in propor‐
tion to the membrane potential. The proportion of mitochondria with lower fluorescence
intensity, which represents the depolarized mitochondria, was increased post propionate
treatment  in  a  dose-  and time dependent  manner  in  the  colon cancer  cells  treated.  The
study  in  references  [21,  23]  demonstrated  that  propionate  causes  mitochondrial  defect
leading  to  ATP depletion  and  release  of  reactive  oxygen  species  (ROS).  Excessive  ROS
levels  have been attributed to  induction of  autophagy.  The defective  mitochondria  post
treatment is removed by a selective autophagy process known as mitophagy. Mitophagy
will  be  discussed in  the next  section and how it  is  regulated in  colon cancer  cells  post
propionate treatment.
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6.2. Propionate treatment causes mitophagy in colon cancer cells
Mitochondria are cells organelles that primarily produce ATP via oxidative phosphoryla‐
tion in the inner membrane of the mitochondria. During changes in the environment, ATP
synthesis can be disrupted leading to the production of reactive oxygen species (ROS) and
release  of  proteins  to  promote  cell  death.  Several  pathologies  have  impaired  mitochon‐
dria,  oxidative  stress,  accumulation of  protein  aggregates  and autophagic  stress.  Oxida‐
tive stress can lead to the nonspecific modification of proteins and contributes to protein
aggregation. Interestingly, the cell can adopt its own defense mechanism against aberrant
mitochondria, which can be harmful to the cell  [24].  This mechanism termed mitophagy
was  first  observed  in  mammalian  cells  by  early  electron  microscopy  studies,  where
increased mitochondrial  sequestration was identified in lysosomes following stimulation
of hepatocytes catabolism with glucagon [25]. This selective autophagy process is character‐
ized by the removal of excess or damaged mitochondria in order to prevent activation of
apoptotic cell death [26]. Mitophagy has been shown to play a role during cellular quality
control. For instance, in yeast and in mammalian cells, mitophagy is preceded by mitochon‐
drial  fission,  which  divides  elongated  mitochondria  into  pieces  of  manageable  size  for
encapsulation and also quality control of segregation of damaged mitochondrial material
for selective removal by mitophagy. Another process, mitochondrial fusion, occurs every
5 to 20 minutes and was shown to reduce mitochondrial depolarization in two cell lines
(COS7  and  INS1).  Mitochondrial  fission,  fusion  or  mitophagy  are  all  important  for
mitochondrial homeostasis [27]. Mitophagy has also been shown to be required for steady-
state turnover of  mitochondria,  for  the adjustment of  mitochondrion numbers to chang‐
ing metabolic requirements and during specialized developmental stages in mammalians
cells such as during red blood cell  differentiation [25].  Some important proteins such as
ULK1 and ULK2 (two Atg1 homologues), Parkinson’s disease genes α-synuclein, parkin,
PINK1 and DJ-1 are all involved in mitophagy. During the selection of mitochondria for
mitophagy,  mitochondrial  components  of  the  cell  are  identified  by  partner  cytosolic
proteins such as Parkin or Nix that bind to the surface and tag it for degradation [24-26].
Treatment  of  colon  cancers  cells  HCT116  with  propionate  resulted  in  reduced  staining
intensity  of  mitochondria  and  an  increased  colocalization  between  mitochondria  and
punctuates  GFP-LC3.  COXIV,  a  mitochondrial  marker  was  also  reduced and was  local‐
ized  as  defective  mitochondria  by  autolysosomes.  An  ubiquitin-binding  protein-p62,  a
protein  that  interacts  with  LC3  and  regulates  autophagosome  formation,  significantly
colocalized with mitochondrial COXIV. Flow cytometry analysis showed that most of colon
cancer cells  treated with propionate showed a reduced Mito Tracker Deep Red staining
and enhanced GFP-LC3 fluorescence. Addition of chloroquine, an inhibitor of autophagic
degradation,  dramatically  increased the  accumulation of  defective  mitochondria.  All  the
experiments performed in HCT116 colon cancer cells post treatment suggest that propio‐
nate triggers mitophagy. This mitophagy selectively targets mitochondria with a depolor‐
ized membrane potential [21, 23].
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Figure 5. Mechanisms of mitophagy and representation of proposed role of short chain fatty acids on mitochondria.
Treatment of colon cancer cells with SCFAs depolarizes and damages the mitochondria. Reduced mitochondrial mem‐
brane potential leads to the accumulation of phosphatase and tensin homolog-induced putative kinase 1 (PINK1) and
recruitment of the E3 ubiquitin ligase Parkin to mitochondria. Parkin, then promotes the ubiquitination of proteins in
the mitochondrial membrane, which targets the damaged mitochondrion for removal by an autophagasome.
6.3. Short chain fatty acids and lipid metabolism in colon cancer cells
Interestingly,  treatment  of  HCT116  cells  with  propionate  altered  the  lipid  metabolism.
Lipids  play  an  important  role  in  cell  structure  and  metabolism.  Post  treatment  with
propionate, the expression of fatty acid synthase, the enzyme that catalyzes the synthesis
of  long  chain-fatty  acids  (LCFAs)  from  acetyl-CoA  (ACC)  and  malonyl-CoA,  was  re‐
duced. Furthermore, GSK-3β, which inhibits endergonic glycogen synthesis by phosphory‐
lation and activation of glycogen synthase, was also downregulated. AMPK kinase, which
was increased post  propionate treatment  further  phosphorylates  and inhibit  acetyl-CoA,
thus de novo lipid synthesis. The inactivation of ACC by AMPK mediates the increase in
mitochondrial import and oxidation of LCFAs, resulting in the generation of ATP.
Energy deprivation can stimulate mitochondrial biogenesis in skeletal muscle in an AMPK-
dependent manner. When the effects of propionate treatment in mitochondrial biogenesis
were investigated, the mRNA levels of nuclear gene mitochondrial transcription factor A
(Tfam) and mitochondrial transcription factor B (mtTFB) were stimulated, peaking at 8.5
and  11.5  h  respectively,  before  returning  to  the  initial  pre-stimulatory  levels.  Other
transcription  factors  related  to  heme  biosynthesis  and  mitochondria  biogenesis  named
nuclear  respiratory  factors-1  and  2  (NRF-1  and NRF-2)  and  polymerase  gamma (pol-γ)
expression were also stimulated at the mRNA level in colon cancer cells after propionate
treatment. On the other hand, peroxisome proliferator activated receptor-γ was reduced.
Autophagy - A Double-Edged Sword - Cell Survival or Death?242
Moreover, an increase in mitochondria complex subunits and increase in Mitotracker greem
FM  fluorescence  also  indicated  and  confirmed  that  HCT116  cells  adapt  to  propionate-
induced ATP depletion by downregulating anabolic processes such as glycogen and lipid
synthesis,  while  stimulating  mitochondrial  biogenesis  in  an  attempt  to  resume  cellular
energy homeostatis [21, 23].
6.4. Propionate, autophagy and apoptosis
Autophagy and apoptosis are two programmed-cell deaths that may be interconnected and
even simultaneously regulated by the same trigger in tumor cells. During apoptosis, cells
are destroyed as an end result  of caspase mediated destruction of the cellular structure.
There exist  two core pathways inducing apoptosis:  the extrinsic  and intrinsic  pathways.
The extrinsinc pathway is triggered by the Fas death receptor (DR), which depends on the
combination of FasL and Fas. The other process, the intrinsic pathway leads to apoptosis
upon sensing of an extracellular stimuli or intracellular signal that renders the mitochondri‐
al membrane permeable and releases cytochrome c [28-31].
Molecular  pathways  leading  to  cancer  can  cross-talk.  Autophagy  and  apoptosis  can
particularly act as partners to induce cell  death in a coordinated or cooperative fashion.
Although  both  can  be  triggered  by  common  upstream  signals,  this  will  have  different
effects on the cell fate. For instance, autophagy can function as a double edged sword to
either  promote  or  inhibit  cell  death.  In  most  cases,  inhibition of  autophagy leads  to  an
increase susceptibility to apoptotic stimuli [29]. For instance when colon cancer cells were
treated with propionate, [21] found that the induction of autophagy has a protective effect
on HCT116 cells. SCFAs were previously shown to induce caspase-3-mediated apoptosis.
Cotreatment of colon cancer cells (HCT116 and SW480) with 3-methyladenine (3-MA), an
inhibitor  of  autophagy,  significantly  reduced  the  percentage  of  GFP-LC3  formation.
However, 12 h after the initiation of treatment of propionate/3MA, the number of apoptot‐
ic cells increased as indicated by the high annexin-V staining. Western blot analysis also
revealed increased cleavages of the pro-apoptotic cascapase-7 and executioner caspase-3,
which are all  critical  mediators of  the mitochondrial  events of  apoptosis  in cells  treated
with  propionate/3MA  compared  to  nontreated  group.  Addition  of  another  inhibitor  of
autophagy, chloroquine, enhanced apoptosis in HCT116 cells, especially at the later stages
of treatment. Since depletion of AMPKα using shRNA was also shown to mimic the effects
of autophagy silencing,colon cancer cells depleted of the AMPKα were also treated with
propionate.  AMPKα  depleted  cells  showed  a  more  significant  cytotoxicity  post  propio‐
nate treatment.  Further depletion of autophagy by knocking down ATG5 expression, an
important protein required for autophagy, reduced the ability of propionate to induce GFP-
LC3 punctae formation, indicating successful depletion. This inhibition of autophagy also
confirmed the protective role of autophagy in colon cancer cells post treatment with the
short chain fatty acid, propionate.  All  the findings by [21, 23] suggested that autophagy
confers a protective role in propionate-mediated cell death in colon cancer cell.
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Figure 6. Proposed model for regulation of autophagy by short chain fatty acids in colon cancer cells. Treatment of
colon cancer cells with short chain fatty acids increases ROS levels, lowers the mitochondrial membrane potential and
ATP levels. This results in a reduction of cellular energy and defects in mitochondria. As a result, downstream signaling
pathway AMPK is activated while mTOR is inhibited and resulting in the activation of autophagy. At the same time,
defective mitochondria is removed by a process known as mitophagy in order to rescue the cells from apoptosis and
cell death. The activation of autophagy has a protective role on the cell as it prevents cell death.
7. Conclusion
Short chain fatty acids are the major by-products of bacterial fermentation of undigested fibers
in the colon. Short chain fatty acids, particularly propionate has been shown to promote
differentiation, growth arrest and apoptosis in colon cancer cells. Furthermore, SCFAs can
promote autophagy to retard mitochondrial defect stimulated apoptosis. Although the in vitro
studies demonstrated a role of short chain fatty acids in promoting autophagy and protecting
the cells from apoptotic death, the relevance of this finding has yet to be investigated in vivo.
Moreover, cotreatment of colon cancer cells with SCFAs and chloloroquine, an inhibitor of
autophagy may be an effective therapy approach to be investigated.
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